77
Participants
Start Date
January 31, 2009
Primary Completion Date
March 31, 2013
Study Completion Date
December 31, 2016
IB1001
Study Part 1: Randomized, double-blind, cross-over study with IB1001 and nonacog alfa; Study Part 2: Non-randomized, open-label evaluation of prophylaxis and on demand IB1001; Surgical Sub-study: Open-label evaluation of IB1001 during major surgery
nonacog alfa
Study Part 1: Randomized, double-blind, cross-over study with IB1001 and nonacog alfa
The Children's Hospital of Philadelphia, Philadelphia
Emory University School of Medicine Pediatric Hematology, Atlanta
Centre Regional de Traitement de l 'Hemophilie, Nantes
Hemophilia and Thrombosis Center, Cincinnati
Indiana Hemophilia & Thrombosis Center, Indianapolis
The National Hemophilia Center-Sheba MC, Tel Litwinsky
University of Minnesota Center for Bleeding and Clotting Disorder, Minneapolis
Rush University Medical Center-Pediatric Hematology Oncology, Chicago
Hopital Edouard Herriot, Lyon
University of Texas Health Science Center-Houston, Gulf States Hemophilia & Thrombophilia Center, Houston
Hemophilia Treatment Center of Las Vegas, Las Vegas
The Hemophilia Treatment Center of Orthopaedic Hospital, Los Angeles
City of Hope, Duarte
Sahyadri Specialty Hospital, Deccan Gymkhana, Pune
Jehangir Clinical Development Centre, Pune
Ospedale di Careggi, Florence
University of Milan, Milan
MTZ Clinical Research, Warsaw
Royal Free Hospital, London
Manchester Haemophilia Comprehensive Care Manchester Royal Infirmary, Manchester
Royal Hallamshire Hospital, Sheffield
Centre for Haemostasis and Thrombosis, Basingstoke and North Hampshire Foundation Trust, Basingstoke
University Hospital of Wales Health Park, Cardiff
Lead Sponsor
Medexus Pharma, Inc.
INDUSTRY